Access cutting-edge multiple sclerosis (ms) - relapsing-remitting treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Baltimore location
Preparing your pre-screening questions…
Access multiple sclerosis (ms) - relapsing-remitting specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple sclerosis (ms) - relapsing-remitting treatment provided free
Check if you qualify for this multiple sclerosis (ms) - relapsing-remitting clinical trial in Baltimore, MD
No-Cost Study Care
Local to Baltimore
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a new manner. In order to assess this new biomarker, a specialized optical coherence tomography (OCT) scan will be performed at enrollment into the study and at 2 other timepoints throughout the study. Subjects asked to take part in this study should have been diagnosed with relapsing multiple sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication for the treatment of their MS. We plan to enroll 30 patients into this study. Fifteen (15) patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being initiated on B-cell depletion therapy by their treating physician at the University of Maryland Center for MS Treatment and Research will be offered enrollment into this study. Additionally, 15 age/sex matched patients with stable RRMS who are not undergoing any change in treatment and are not currently on B-cell depleting therapies will be enrolled as control subjects.
Sponsor: University of Maryland, Baltimore
Yes, this clinical trial (NCT06864936) has an active research site in Baltimore, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for multiple sclerosis (ms) - relapsing-remitting treatment options in Baltimore, MD, this clinical trial (NCT06864936) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis (ms) - relapsing-remitting specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all multiple sclerosis (ms) - relapsing-remitting clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Baltimore — not just this study.
Browse Heart Attack Trials in Baltimore →